ArticleDiabetes care2023
Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts.
Abstract readComment
In one paragraph
Article in Diabetes care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.Endocrinology and metabolism (Seoul, Korea) · 2025 · on this mapPooled it
- Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.International journal of molecular sciences · 2024Pooled it
- Papillary thyroid carcinoma discovered in a patient on semaglutide therapy for metabolic syndrome: a case presentation and review of current evidence.Hormones (Athens, Greece) · 2026Review
- Glucagon-like peptide-1 medicines and cancer.Nature cancer · 2026Review
- Investigating the association between incretin-based therapies and thyroid cancer incidence among US Medicare beneficiaries with diabetes.BMJ open diabetes research & care · 2025Article
- Association of GLP1-Receptor Agonists with Risk of Hepatocellular Carcinoma: A Retrospective Cohort Study.Drug safety · 2025Article
- The effects of incretins as a double-edged sword on cancer.Molecular biology reports · 2025Review
- Semaglutide Reprograms Macrophages via the GLP-1R/PPARG/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth.The Journal of clinical endocrinology and metabolism · 2025Article
- The Relationship Between Obesity and Cancer: Epidemiology, Pathophysiology, and the Effect of Obesity Treatment on Cancer.Current oncology (Toronto, Ont.) · 2025Review
- Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies.Journal of the American Society of Nephrology : JASN · 2025Review
- GLP-1RA Use and Thyroid Cancer Risk.JAMA otolaryngology-- head & neck surgery · 2025Article
- Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network : Author list.Journal of endocrinological investigation · 2025Article
- A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment.Pharmacological reports : PR · 2024Review
- Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.BMJ (Clinical research ed.) · 2024Article
- Thyroid cancer and insulin resistance.Reviews in endocrine & metabolic disorders · 2024Review
- Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?Endocrine connections · 2023Review
- Diagnosis and Non-Invasive Treatment of Obesity in Adults with Type 2 Diabetes Mellitus: A Review of Guidelines.Journal of clinical medicine · 2023Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Caroline A ThompsonORCID 0000-0001-9990-9756
Til StürmerORCID 0000-0002-9204-7177
Funding
Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6MOil and Gas as Drivers of Climate Change and Health: Developing unique resources to investigate multi-level and diverse effects of exposure to oil and gas wellsU01CA199277 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI LACEY, JAMES V, MARTINEZ, MARIA ELENA · 2015 to 2024
$20.7MUnderstanding Pathways to Earlier Diagnosis for Ovarian Cancer in North CarolinaU48DP006400 · DP · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AMMERMAN, ALICE S, LEEMAN, JENNIFER · 2018 to 2023
$9.3MPropensity scores and preventive drug use in the elderlyR01AG056479 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Til Sturmer · 2017 to 2026
$5.0MUnderstanding the Multilevel Drivers of Liver Cancer DisparitiesR01CA225478 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHARIFF-MARCO, SALMA · 2019 to 2023
$3.5MRacial Differences in Treatment with Hysterectomy: a Multilevel InvestigationR01MD011680 · NIMHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBINSON, WHITNEY RAGAN · 2017 to 2021
$3.3MDiagnosis of Cancer in the Emergency Room - Explaining Persistent Disparities - Diversity SupplementR01CA264176 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THOMPSON, CAROLINE AVERY · 2021 to 2025
$2.0MMethods for Estimating Sex Differences in Safety and Effectiveness of DrugsR01HL118255 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JONSSON FUNK, MICHELE LAURA · 2014 to 2017
$1.7MPROMIS Validation in Prospective Population-based Prostate Cancer Research StudyR01CA174453 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHEN, RONALD, REEVE, BRYCE B · 2012 to 2016
$1.4MACL HHS U48DP006400NCATS NIH HHS UL1 TR002489NCCDPHP CDC HHS U48 DP006400NCI NIH HHS R01 CA174453NCI NIH HHS R01 CA225478NCI NIH HHS R01 CA264176NCI NIH HHS U01 CA199277NHLBI NIH HHS R01 HL118255NIA NIH HHS R01 AG056479NIMHD NIH HHS R01 MD011680
Abstract
PubMed holds no abstract for this paper.
Indexed as
Diabetes Mellitus, Type 2Thyroid NeoplasmsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsHumansHypoglycemic AgentsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.